Phaseline

Targets › AKT2

AKT2 (RAC-beta serine/threonine-protein kinase): drug programs, companies and trials

7 programs from 6 companies in 51 trials: 22 Phase 2, 17 Phase 1, 12 Phase 3; Oncology, Other, Gastroenterology; next expected readout Nov 2026.

Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and AKT3, are collectively known as AKT kinase. (UniProt, P31751)

Open in Phaseline: the race on AKT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaCapivasertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer; Prostate Cancer; Triple Negative Breast Neoplasms; Breast Cancer …Nov 2026
LaeknaAfuresertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Breast CancerDec 2026
RocheIpatasertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Cancer; Ovarian Cancer; Solid Tumors; Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer …Feb 2028
National Cancer Institute (NCI)Uprosertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2Recurrent Uveal MelanomaJul 2027
Merck & Co. (MSD)Miransertib (MK-7075)
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS); Proteus SyndromeFeb 2030
QuantumLeap Healthcare CollaborativeMK-2206
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2Breast NeoplasmsDec 2030
National Cancer Institute (NCI)Mk-2206 (MK2206)
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 1Advanced Malignant Solid NeoplasmMar 2027

Conditions

Breast Cancer (5) Metastatic Breast Cancer (4) Advanced Lymphoma (3) Locally Advanced (Inoperable) or Metastatic Breast Cancer (2) Prostate Cancer (2) Triple Negative Breast Neoplasms (2) Hormone-Sensitive Prostate Cancer (1) Locally Advanced or Metastatic Breast Cancer (1) Moderate Hepatic Impairment (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) CCCA Assessed by Ki67 Drop Below <2.7% From Baseline (1) Premenopausal Breast Cancer (1)

Modalities

mixed (4), small molecule (3)

Companies

National Cancer Institute (NCI) (2) AstraZeneca (1) Merck & Co. (MSD) (1) Roche (1) Laekna (1) QuantumLeap Healthcare Collaborative (1)

Related targets

AKT3 (7) AKT1 (7)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.